Economic evaluation of Cytosponge®-trefoil factor 3 for Barrett esophagus: A cost-utility analysis of randomised controlled trial data

Economic evaluation of Cytosponge®-trefoil factor 3 for Barrett esophagus: A cost-utility analysis of randomised controlled trial data

Background: Esophageal adenocarcinoma has a very poor prognosis unless detected early. The Cytosponge-trefoil factor 3 (TFF3) is a non-endoscopic test for Barrett esophagus, a precursor of esophageal adenocarcinoma. Randomised controlled trial data from the BEST3 trial has shown that an offer of Cyt...

Full description

Bibliographic Details
Main Authors: Nicholas Swart, Roberta Maroni, Beth Muldrew, Peter Sasieni, Rebecca C. Fitzgerald, Stephen Morris
Format: Article
Language:English
Published: Elsevier 2021-07-01
Series:EClinicalMedicine
Subjects:
Screening
Cancer prevention
Early detection
Esophagus
Neoplasia
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537021002492

Internet

http://www.sciencedirect.com/science/article/pii/S2589537021002492

Similar Items